Welcome to Roche HIV website
Home Disclaimer Glossary Library cart Links
Http://www.roche-hiv.com
  
Last updated on : 16-Sep-03


 Roche in HIV
A record of achievement
 and major commitment



Roche is at the forefront of efforts to combat HIV and AIDS, committed for 15 years to ground-breaking research and development of award-winning new drugs and diagnostic technology, to provide tailored treatment solutions and an improved standard of care worldwide for those people living with HIV.

 
       
INNOVATING HIV CARE-DEVELOPMENT OF NOVEL PHARMACEUTICALS AND DIAGNOSTICS STATEGIES TO ADDRESS KEY UNMET MEDICAL NEEDS IN HIV/AIDS
2003 FUZEON® antiviral activity maintained through 48 weeks
EU regulatory filing for Roche's new VIRACEPT® 625 mg formulation
FUZEON® receives European approval
FUZEON® receives US approval
COBAS AMPLICOR HIV-1 MONITOR™ Test Version 1.5 (automated version) receives US approval
Regulatory filing for the first HIV fusion inhibitor, FUZEON® (enfuvirtide) 2002
Roche licences in a new-generation, preclinical NNRTI from Medivir  
Entry into humans for Roche’s new protease inhibitor R944
EU approval for boosted saquinavir/ritonavir 1000/100 mg bid
AMPLICOR HIV-1 MONITOR® Test Version 1.5 receives US approval (can additionally detect and quantify non-B HIV subtypes)
2001 VALCYTE® (valganciclovir) receives US and EU approval for treatment of AIDS-related CMV retinitis
Phase III studies begin with the first HIV fusion inhibitor 2000
Roche presents data on the first HIV resistance assay using micro-array chip technology  
1999 AMPLICOR HIV-1 MONITOR® Ultra Sensitive Method approved (measures down to 50 HIV RNA copies/ml)
Roche initiates research and development collaboration with Trimeris Inc on inhibition of HIV fusion
             
VIRACEPT® (nelfinavir) approved in EU 1998  
1997 Approval for new formulation of saquinavir: FORTOVASE®
AMPLICOR HIV-1 MONITOR® Test approved (measures down to 400 HIV RNA copies/ml) 1996
1995 INVIRASE® (saquinavir), the first protease inhibitor, introduced
CYMEVENE®/CYTOVENE® (ganciclovir) capsules approved for treatment of CMV retinitis in HIV 1994
1992 HIVID® (zalcitabine) approved
Qualitative AMPLICOR® PCR test approved
IV ganciclovir approved for HIV induction therapy 1989  
  1987 First Roche HIV antibody test introduced
Roche initiates protease project 1986
ROFERON-A® (interferon alfa-2a) approved for Kaposi’s sarcoma  
 

 

 

 

Home | Disclaimer | Site map | Glossary | Library cart | Links | Keep me informed | Roche worldwide
  Copyright 2001 F. Hoffmann-La Roche Ltd.   DISCLAIMER